Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of dexamethasone nanoparticles eye drops in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: anti-inflammatory or anti-angiogenic drugs play an ever- increasing role in the treatment of diabetic macular edema (dme). the drug delivery systems, such as injections of corticosteroid and or vascular endothelial growth factor (vegf) antibodies into the vitreous cavity or slow release drug capsules surgically implanted in the eyes run the risk of surgical complications including infections, hemorrhages and cataracts and place a huge demand on eye care resources significantly increase the risk of cardiovascular events and death. a non-invasive drug delivery platform with steroid eye drops, reaching the back of the eye to treat dme and other retinal diseases would circumvent most of these problems. a novel drug delivery platform is required for ocular therapy. oculis ehf. has developed a drug delivery platform, which is based on cyclodextrin nanoparticles that dissolve in the tear fluid to form water-soluble drug/cyclodextrin complex nanoparticles. animal and initial clinical testing has shown the potential for this technology to increase the drug concentration in the eye tissues including the retina and therefore treat retinal diseases like dme.


Eligibility criteria:
key inclusion criteria: 1. had dme of less than 3 years duration since diagnosis with presence of intraretinal and/or subretinal fluid in the study eye, with cmt of ≥ 310 µm by sd-oct at baseline (visit 2) (as measured by the investigator). 2. had definite retinal thickening in the study eye due to dme involving the central macula based on the investigator's clinical evaluation and by sd-oct; ... key exclusion criteria: 1. had macular edema considered to be due to a cause other than dme; 2. had a decrease in bcva due to causes other than dme (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, previous vitreoretinal surgery, central serous retinopathy, non-retinal condition, substantial cataract, macular ischemia) that is likely to be decreasing bcva by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal). ...
tertiary care for visual developmental disorders in pre-school children

Conditions: Visual Developmental Disorders

Summary: visual development disorders are major public health problems among children especially in china. how to find an effective and economic way to manage the larger number of children in china remains exploring. the national basic public health services of china offer visual acuity screening for preschool children for free every year. the aim of this study is to demonstrate the feasibility, cost-effective and the influence factors of compliance of tertiary care for visual developmental disorders in pre-school children after screening, and whether this disease management model is more effective and superior than the current medical care in china.

visual development disorders including amblyopia , strabismus ,refractive error are an important public health problem among children, and the visual impairment caused by visual development disorders is lifelong and can be profound. timely discovering and treatment of visual development disorders are significant for the recovering of visual function in children. the national basic public health services of china offer the basic visual acuity screening every year for free. in this study, the investigators try to explore the cost-effective and compliance of the national basic public health services based tertiary care model for the management of visual development disorders among preschool children. this tertiary care based on disease management model among preschool children was conducted at yudu county, jiangxi province, in china. preschool vision screening relied on the national basic public health services of china (refractive errors examined by the retinomax autorefractor). children who failed the screening were randomized into two groups, the intervention group: their parents will be informed and transferred to an ophthalmologist and optometrist at ophthalmic referral center, receiving basic eye examination and therapy (visual corrected by glasses and periodic review); the control group: their parents will be informed and suggest them to take their children to the hospital for further examination by themselves.

Eligibility criteria:
inclusion criteria: 1. patients who are aged 4-7 years and of chinese citizen 2. who is willing to sign the consent form 3. children at the kindergarten will receiving the eye diseases screening of public health equalization programs in china, and there are abnormal findings after screening exclusion criteria: 1. unwilling to sign the consent form 2. exiting eye diseases and already receiving therapies and follow up

Keywords: myopia tertiary care pre-school children
a study of spg block for opioid withdrawal

Conditions: Opioid Use Disorder

Summary: medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. however, many patients experience withdrawal symptoms, which prevents them from being successfully inducted onto medication for opioid use disorder. this study is a pilot study investigating whether blocking the spg helps reduce withdrawal symptoms in oud. this study does not involve treatment or induction onto medications. it is a proof of principal study only. we will recruit non-treatment seeking subjects with oud who are admitted to the research unit for all procedures.

the sphenopalatine ganglion (spg) is a collection of neurons involved in autonomic regulation (which refers to bodily processes that are automatic like heart rate and blood pressure). blocking the spg is used to treat disorders, such as migraines or cluster headaches (short, severe headaches that occur together). the procedure will be performed by a doctor (specialized in ear, nose throat surgery) and would first involve the application of numbing nasal spray to both nostrils, which lasts about two hours and might reduce smell during that time. this is followed by an injection of a stronger numbing agent (similar to the type used by dentists) to the nerve bundles in the back of the nasal passages (one side at a time) via a tool, known as an endoscope which is a rigid tube with a camera on the end. the procedure is not painful. previous studies have shown that clonidine, which inhibits the autonomic nervous system, is helpful for reducing the symptoms of opioid withdrawal. however, the dosing of clonidine is limited by side effects (lowered blood pressure and heart rate) and compliance. furthermore, withdrawal is among the most significant barriers to substance treatment and ultimately overcoming a substance use disorder. thus, we would like to explore whether a more targeted intervention would improve rates of successful acute detoxification while overcoming the aforementioned challenges of systemic side effects and compliance issues observed with the use of oral agents.

Eligibility criteria:
inclusion criteria: * opioid use disorder, moderate to severe * ages 22 to 50 * lives in new york city, able to travel for visits * willing to be admitted to an inpatient unit exclusion criteria: * medical disorder, for who study participation could be deleterious (neurologic, cardiac, renal or infectious disease * hypertension: bp \> 150/100 * elevated liver function tests (ast, alt) \> 3x normal * having a painful medical illness for which opioids are needed (including upcoming surgery).
follow-up the health condition , investigation of the immuno-regulation , and the study for interaction of viral hepatitis--- among patients with or after dengue fever infection

Conditions: Dengue

Summary: originally test host's to understand the tracking healthily and immune change of the dengue fever in taiwan. blood drawing 20 c.c for liver examination, kidney and other biochemical function, analyze host immunity adjusts and controls the gene, and the reciprocation that may be produced with the virus hepatitis, besides collected 10 c.c urine at the same time. urine check is in order to compare acute infect and infected over three month person, the change of chemical composition. this plan expect to collect 150 healthy, 150 dengue fever infected and 150 dengue fever bleed hot or dengue fever shock disease group's patient, goal to understand health state and immunity of follow-up adjust and control the difference of the gene and the reciprocation may produce to virus hepatitis of light disease and serious disease.

the dengue fever is an important tropical infectious disease in the south of taiwan, cause and threaten of public health at kaohsiung and ping-dong all over the years, this will cause patient's death, the default of clinical change of dengue fever, acute infect, infect influence, host immunity adjust and control, and the reciprocation of virus hepatitis, will be a very urgent in basic research. originally test host's to understand the tracking healthily and immune change of the dengue fever in taiwan. blood drawing 20 c.c for liver examination, kidney and other biochemical function, analyze host immunity adjusts and controls the gene, and the reciprocation that may be produced with the virus hepatitis, besides collected 10 c.c urine at the same time. this plan expect to collect 150 healthy, 150 dengue fever infected and 150 dengue fever bleed hot or dengue fever shock disease group's patient, goal to understand health state and immunity of follow-up adjust and control the difference of the gene and the reciprocation may produce to virus hepatitis of light disease and serious disease. urine check is in order to compare acute infect and infected over three month person, the change of chemical composition. the result of study can help doctor to understand the factor of immune regulation and control of the host and health change after the dengue fever is infected with, possible reciprocation with virus hepatitis. researchers have collect 100 dengue fever bleed hot or dengue fever shock syndrome groups of patient, it is estimated that can collect and expect the case will be counted within two years.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of dengue fever
pecs block in breast surgery: an observational multicenter study

Conditions: Postoperative Pain

Summary: we will enroll patients submitted to breast surgery (in and outsettings) with regional anesthesia. the blinded observers, in the first 48 hours post-operative, will evaluate (telephone interview in outsetting) the pain intensity through the numeric rating scale ( 0= no pain, 10 = worst possible pain) thereby recording the treatment procedures in accordance with usual clinical practice. at the same time we will evaluate the presence of intraoperative or postoperative complications related to regional anesthesia, the ponv rate (post-operative nausea and vomiting) and the analgesic/antiemetic therapy.


Eligibility criteria:
inclusion criteria: asa i-ii-iii patients written informed consent exclusion criteria: asa iv active heart failure coagulation disease chronic pain allergies to local anesthetics

Keywords: breast surgery
non-invasive measurement of cerebral dynamic autoregulation

Conditions: Stroke

Summary: the overall objective of this study is to evaluate the use of diffuse correlation spectroscopy to non-invasively measure dynamic cerebral autoregulation in subjects with vascular risk factors. optical cerebral blood flow measurements will be correlated with changes in arterial blood pressure to assess how cbf is maintained in response to changes in abp, and will be compared to transcranial doppler reference measurements.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 50 years * positive history of at least one of the following vascular disk factors: hypertension, diabetes, hyperlipidemia, coronary artery disease, atrial fibrillation, prior myocardial infarct, transient ischemic attack, or history of smoking exclusion criteria: * vascular risk factor subjects: 1. pregnant women 2. prisoners 3. prior neurosurgical procedure or traumatic brain injury, including hemicraniectomy or other skull defect 4. prior history of ischemic or hemorrhagic stroke 5. prior lower extremity amputation 6. peripheral vascular disease
egcg improves acne by modulating molecular targets

Conditions: Acne Vulgaris

Summary: epigallocatechin-3-gallate (egcg) may improve acne vulgaris * major polyphenolic constituent in green tea * known as potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities * lipid-lowering and antiandrogenic properties was reported * egcg can improve acne vulgaris via one of the above mentioned actions.

acne vulgaris is one of the most prevalent skin disorders of sebaceous follicles, affecting more than 85% of adolescents in united states. acne can persist throughout the adulthood, and even a mild form of acne might progress to permanent scarring on the face, chest and back, thereby causing significant physical and psychosocial morbidities. acne is a multifactorial disease of which etiology has not been fully elucidated, although considerable progress has been made in understanding its pathogenesis during last decade. the major pathogenic features of acne include abnormal ductal keratinization, sebum overproduction, propionibacterium acnes, and inflammation. common acne medications such as topical retinoids, antibiotics and isotretinoin are associated with irritation and incomplete responses, increased bacterial resistance or untoward side events, respectively. thus there is a continuing need for a novel, effective agent targeting different aspects of acne pathogenesis, with minimal side effects. in the recent decade, epigallocatechin-3-gallate (egcg), the major polyphenolic constituent in green tea, has attracted much interest on account of its potent anti-carcinogenic, anti-inflammatory, anti-proliferative, and antimicrobial activities. preclinical, observational, and clinical trial data have indicated that egcg can inhibit tumor initiation, promotion, progression, and angiogenesis. egcg also suppresses neutrophil chemotaxis, and has been suggested to improve many diseases that have inflammatory components such as diabetes, kidney injuries, arthritis, allergies, dental caries, cardiovascular, gastrointestinal, and neurodegenerative diseases. in skin, egcg has been investigated mainly in light of antioxidative, immunopotentiating and anticarcinogenic properties against chemicals or ultraviolet irradiation. moreover, egcg has lipid-lowering and antiandrogenic properties, and can downregulate peroxisome proliferator-activated receptor-γ expression. based on these observations, it can be inferred that egcg might be effective in the treatment of acne.

Eligibility criteria:
inclusion criteria: * age of at least 15 years * clinical diagnosis of mild to moderate acne vulgaris exclusion criteria: * known pregnancy or lactation * any medical illness that might influence the results of the study, * a previous history of oral acne medication or surgical procedures including laser treatment within 6 month and topical medication within 4 weeks of study enrollment.

Keywords: egcg green tea
outpatient clinic for late outcome for breast carcinoma in maastro clinic.

Conditions: Breast Cancer

Summary: in order to evaluate the late outcome in patients curatively treated for breast cancer, a special outpatient clinic will be developed. there are two main purposes of the outpatient clinic. the first purpose is evaluating the results of the radiation treatment by mapping a) late toxicity and b) tumour control and survival. the second purpose is that this outpatient clinic for late outcome will also function as a pilot for a new cat (computer assisted theragnostics, abbreviated cat project) in which multiple late outcome variables will be recorded. in this pilot we want to investigate whether physical presence of the patient on the outpatient clinic, allowing physical examination, has any added value to the questionnaires filled in by the patient at home. the ultimate aim of this new cat project is to use these multicentric data to develop models for predicting both oncological outcome and late side effects. insight in the beneficial and adverse effects of a certain treatment using these predictive models, will be required choose the optimal treatment for the individual patient using a shared decision making process.


Eligibility criteria:
inclusion criteria: * all patients treated for breast cancer with curative intent in maastro clinic in 2002-2003 who are still alive. * consent to invitation letter and willing to participate. exclusion criteria: * treatment without curative intent. * no consent to invitation letter

Keywords: outpatient clinic breast cancer late toxicity
hippocampal and thalamic dbs for bilateral temporal lobe epilepsy

Conditions: Epilepsy, Temporal Lobe

Summary: the study aims to compare the safety and effectiveness of deep brain stimulation of the hippocampus and the anterior nucleus of the thalamus for reducing the frequency of seizures in patients with bilateral temporal lobe epilepsy.

the outcome of resective surgery for bilateral temporal lobe epilepsy (btle) is poor. neuromodulation such as deep brain stimulation is an alternative therapy for patients with drug-resistant epilepsy, especially for those not suitable for resective surgery. this prospective, randomized, open-label trial aims to compare the effectiveness of deep brain stimulation of the hippocampus and the anterior nucleus of the thalamus for bilateral temporal lobe epilepsy.

Eligibility criteria:
inclusion criteria: 1. patients between 12 to 60 years old. 2. bilateral temporal lobe epilepsy patients proved by veeg or seeg. 3. at least 3 seizures per month but not more than 10 seizures per month, and the longest seizure interval is no more than 30 days during the baseline. 4. patients failed to at least 3 antiepileptic drugs (aeds), and are receiving at least 1 aeds now. 5. be able to complete seizure diary. 6. agree to participate this study and sign informed consent. exclusion criteria: 1. extratemporal lobe epilepsy or with potential extratemporal epileptogenic focus. 2. patients with psychogenic non-epileptic seizures. 3. iq \< 70, or unable to complete the study. 4. patients are pregnant or plan for it. 5. patients with implanted electrical stimulation medical device. 6. patients with other severe neuropsychiatric disorders such as dementia, schizophrenia, or neurodegenerative diseases. 7. patients with cerebral lesions which unsuitable for lead implantation.
a study to assess safety and feasibility of direct infusions of donor-derived virus-specific t-cells in recipients of hematopoietic stem cell transplantation with post-transplant viral infections using the cytokine capture system®

Conditions: Adenovirus Infection; EBV; Cytomegalovirus Infections; Cytokine Capture System; Allogenic Disease

Summary: to assess the feasibility of donor-derived interferon (ifn)-γ positive select-ed virus-specific t-cells using the cytokine capture system® (ccs) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (hsct) with treatment refractory post-transplant viral infections. the ccs has already been successfully used in clinical studies in germany and united kingdom (uk).


Eligibility criteria:
inclusion criteria: * adults \> 18 years of age * undergone allogeneic hsct * written informed consent * patients with treatment refractory infections with adenovirus, cytomegalovirus (cmv) or epstein-barr virus (ebv) will be included in case of fulfilling following criteria: patient with adenovirus infection: 1. antiviral treatment with cidofovir for at least 7 days * no virus load decrease ( ≤ 1 log) or virus load increase on treatment for at least 7 days or * cluster of differentiation 3 (cd3) + cells \< 300/µl on treatment for at least 7 days 2. or if antiviral treatment is contraindicated patient with ebv: 1. after receipt of at least one anti-cluster of differentiation 20 antigen (cd20)-antibody treat-ment (375 mg/m2) * no virus load decrease (≤ 1 log) or virus load increase 7 days after receipt of treatment or * cd3+ cells \< 300/µl 7 days after receipt of treatment or * clinical progression patient with cmv: 1. antiviral treatment with ganciclovir or foscavir for 14 days - no virus load decrease (≤ 1 log) or virus load increase on day 14 2. or if \> 2 recurrences despite antiviral treatment with ganciclovir or foscavir for 14 days and cd3+ cells \< 300/µl 3. or if antiviral treatment is contraindicated - patient exclusion criteria: * graft-versus-host disease (gvhd) \> grade 2 at the time point of planned infusion * known allergy to iron-dextran or murine antibodies
serum angptl3, angptl8 and glypican 4 concentrations in relation to the development of obesity in korean children

Conditions: Obesity

Summary: angptl3 and angptl8 are emerging molecules involving lipid metabolism. in previous in vivo study using mice, angptl8 regulated the activation of angptl3 which was known to inhibit lipoprotein lipase activity and stimulate lipolysis of adipose tissue. besides, glypican 4 was identified as a novel adipokine modulating adipocyte differentiation. thus, the investigators postulated that different serum concentrations of angptl3, angptl8 and glypican 4 might affect progression of obesity in children. the investigators measure these molecules in korean children, and investigate the association between these molecules and development of obesity.

participants in this study were selected from the korean metabolic disorders \& obesity study in elementary school children (kmoses), the main aim of which was to comprehensively assess obesity-related metabolic risk factors and to evaluate clinical outcomes in korean children prospectively. korean children who were participated in a school-based health examination, were reexamined for the 3-year follow-up assessment.

Eligibility criteria:
inclusion criteria: * participants who were reexamined for the 3 year follow-up assessment exclusion criteria: * participants who were not being available for the 3 year follow up assessment
invasive pneumococcal disease study

Conditions: Pneumococcal Infections; Pneumococcal Conjugate Vaccine; Antibiotic Treatment; Mortality

Summary: after 7 then 13 valent pneumococcal conjugate vaccine implementation in france in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (ipd). we will describe the clinical characteristics of ipd, pneumococcus serotyping, underlying conditions and vaccination status.


Eligibility criteria:
inclusion criteria: * isolate of streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood pcr. exclusion criteria: * pneumococcal strain not transmetted to national reference center for pneumococci or to regional pneumococci observatory